Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients

PURPOSE: Multiple myeloma (MM) patients with triple- and penta-refractory disease have a poor survival and limited treatment options. Selinexor, in combination with bortezomib and dexamethasone, demonstrated clinical activity in the STOMP study as well as in the BOSTON study in previously treated pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Delforge, Michel, Raddoux, Jolien, Antonis, Corine, Clement, Céline, Kint, Nicolas, Vanhellemont, Anneleen, Bravetti, Julie, Vandenberghe, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932935/
https://www.ncbi.nlm.nih.gov/pubmed/35310960
http://dx.doi.org/10.2147/OTT.S341120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932935/
https://www.ncbi.nlm.nih.gov/pubmed/35310960
http://dx.doi.org/10.2147/OTT.S341120

Ejemplares similares